As part of the Agios deal Servier also took rights to vorasidenib – a dual inhibitor of mutated IDH1 and IDH2 – that is in trials for a hard-to-treat form of brain cancer called glioma.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback